Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients

Summary

Vascular calcification is a frequent complication in dialysis patients and is strongly associated with mortality. Its pathogenesis is complex and involves a series of markers that act on the vascular microenvironment. There is evidence that aldosterone is one of the biomarkers and may have a role in osteoinductive pathways.The aim of this study was to evaluate the effect of spironolactone, an inhibitor of mineralocorticoid receptor, in the progression of coronary calcification in patients undergoing peritoneal dialysis.

Conditions

• Coronary Artery Calcification
• Vascular Calcification

Interventions

DRUG

Spironolactone 25Mg Tablet

Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months

Sponsors & Collaborators

• Federal University of São Paulo

  collaborator OTHER

• Professor Fernando Figueira Integral Medicine Institute

  lead OTHER

Principal Investigators

• Ana Paula S Gueiros, MD · Instituto de Medicina Integral Prof. Fernando Figueira

• Alex SR Souza, PhD · Instituto de Medicina Integral Prof. Fernando Figueira

• Aluizio B Carvalho, PhD · Universidade Federal de São Paulo

• José E Gueiros, MD · Instituto de Medicina Integral Prof. Fernando Figueira

• Leuridan T Cavalcante, PhD · Instituto de Medicina Integral Prof. Fernando Figueira

• Dulce E Casarini, PhD · Universidade Federal de São Paulo

• Marina M Cadena · Instituto de Medicina Integral Prof. Fernando Figueira

• Karina T Nobrega, MD · Instituto de Medicina Integral Prof. Fernando Figueira

• Eveline B Calado, MD · Instituto de Medicina Integral Prof. Fernando Figueira

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-11-07

Primary Completion

2016-11-10

Completion

2016-11-10

Countries

• Brazil

Study Locations